Glioblastoma: Current Treatment Approach
Transcript of Glioblastoma: Current Treatment Approach
![Page 1: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/1.jpg)
Glioblastoma: Current Treatment Approach8/20/2018
![Page 2: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/2.jpg)
Overview
• What is Glioblastoma?
• How is it diagnosed
• How is it treated?• Principles of Treatment
• Surgery, Radiation, Chemotherapy
• Current Standard of care treatment options
• Treatment in the Elderly
• Treatment in Recurrent Disease
2
![Page 3: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/3.jpg)
Brain Tumors
3
Most tumors are brain mets
![Page 4: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/4.jpg)
Primary Brain Tumors
4
![Page 5: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/5.jpg)
Primary Brain Tumors: Summary
• The most common tumors that is found in the brain are brain metastases, which represent 60-80% of all brain tumors
• Primary brain tumors can be Benign or Malignant• Benign tumors include Meningioma, Schwannoma, Hemangiomas• Malignant tumors include Gliomas, Lymphoma, Malignant
Meningioma
• Gliomas arise from glial cells and neuronal precursor cell, and account for 80% of malignant primary brain tumors
• There are primarily two main subtypes of Gliomas:• Astrocytoma (of which Glioblastoma is the most aggressive form)• Oligodendroglioma• Neurocytoma, Ependymal, Diffuse glioma are other entities
5
![Page 6: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/6.jpg)
Gliomas – molecular “grading”
6
![Page 7: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/7.jpg)
Glioblastoma – two types of disease?
7
![Page 8: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/8.jpg)
Glioblastoma - Histology
• Atypia(High grade tumors)
• Mitosis (Reproduce rapidly)
• Endothelial proliferation• Form its own new
blood vessels (neovascularization)
• Necrosis• Cell will die
8
What is Glioblastoma, what does it look like?
![Page 9: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/9.jpg)
Why do we care about Glioblastoma?
• Overall incidence is only about 3 per 100,000• Compare to Breast cancer
(125) and colon cancer (40)
• It is most common in older patients• Median age of diagnosis is 64
years old• With an aging population, the
incidence may rise
• It is highly aggressive and fatal• Nearly 100% will recur• Median survival is
approximately 15 months• Nearly all patient die from
their disease or treatment
![Page 10: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/10.jpg)
Primary Brain Tumors: Rare cancers
10
![Page 11: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/11.jpg)
Glioblastoma – incidence on the rise
• With an aging population, we are likely to see more patient with high grade glioma
• If patients live longer with the disease (life expectancy about 1 year), then we will need to take care of a larger surviving population of these patients.
11
![Page 12: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/12.jpg)
Timely discussion
2
8/24/20187/19/2017
![Page 13: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/13.jpg)
Risk Factors
• Prior exposure to Ionizing Radiation is the only known risk factor
• Other suspected factors include:• Vinyl chloride, pesticides, smoking, petroleum
• Electromagnetic fields and non-ionizing radiation from cell phones have been evaluated and the data is currently inconclusive whether this increases risks or not
• Specific genetic diseases:• Neurofibromatosis 1 and 2, tuberous sclerosis, Li-Fraumeni
syndrome, retinoblastoma, Turcot syndrome• These represent less than 1% of patients with glioma
13
![Page 14: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/14.jpg)
Glioblastoma
• How do patients present?• Patient is often present with symptoms of
increased intracranial pressure• Headaches• Focal or progressive neurologic deficits
• Seizures may be the presenting symptom and as many as 25% of patients
• Some may present with nonspecific symptoms such as nausea, vomiting, confusion, dementia
• Symptoms may have onset over weeks to months
14
![Page 15: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/15.jpg)
Glioblastoma Work up
MRIContrast enhancing lesionEdema around lesion
15
![Page 16: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/16.jpg)
How to treat Glioblastoma
• Hallmarks of Treatment• Palliation, prevention of symptoms, delay of
recurrence
• Surgery
• Radiation therapy
• Chemotherapy
• Tumor treating fields
• Treatment of recurrent disease
• Palliative care/hospice
16
![Page 17: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/17.jpg)
Case 1
• This is a 66-year-old female with history of breast and endometrial cancer who presented with partial seizures
• She underwent MRI imaging
• She underwent gross total resection
• Pathology reported the following:• Glioblastoma, WHO grade IV• Molecular genetics:
• MGMT is not methylated (poorer prognosis)• No mutation in ATRX gene• No mutation in IDH1 or IDH2 (poorer prognosis)
17
![Page 18: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/18.jpg)
Case 1
18
June 2017 scanT1 post contrast (LEFT)FLAIR (RIGHT)
![Page 19: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/19.jpg)
Treatment: Surgery
• Surgical resection is the mainstay of treatment.• Surgical pathology allows for confirmation of
diagnosis
• Without surgery, prognosis is typically weeks
• Maximal safe resection is standard of care• Studies demonstrate that the more extensive
the resection, the better the outcomes
19
![Page 20: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/20.jpg)
Extent of Resection
20
Increasing the amount resected may improve OSBUT could be biased data
Smaller tumors/better locations may do better
![Page 21: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/21.jpg)
Surgery – pitfalls to gross resection
Tumor is not limited to just the visible massTumor moves along the white matter tracks in the brain
In addition there may be multifocal tumors distributed throughout the brain
Resection of the ‘mass’ only will not eradicate glioblastoma
21
![Page 22: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/22.jpg)
Surgery alone: Poor OS
22
Surgery alone(3-4 months)
Surgery and RT(9-10 months)
![Page 23: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/23.jpg)
Post operative Radiation Therapy
•What is Radiation Therapy?
• Use of ionizing X-rays to cause:
• DNA damage
• Apoptosis
• Cell death
• Immune response
23
![Page 24: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/24.jpg)
Post operative Radiation Therapy
• Cancer cells are more susceptible than normal cells to Radiation because they are more rapidly dividing, and they lack the ability to stop during cell division (no cell cycle arrest) to repair damage.
• Some mutations during radiation could lead to additional cancer genes being turned on in some cancer cells
24
![Page 25: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/25.jpg)
Post op RT standard of care until…
25
BTSG, Walker, Red Journal 1979 RTOG 9803, Tsien, Red Journal 2009
Minimal difference from 55 Gy to 60 GyNo benefit to dose escalationIncreased side effects with increase in dose
Studies looked a various doses of XRT60 Gy/30 fractions/6 weeks appears optimal
![Page 26: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/26.jpg)
What about Chemotherapy
• Several studies have looked at addition of chemotherapy• BCNU
• Most with modest outcomes, but increase is side effects• Gliadel wafers had PFS advantage over placebo
• Until…
26
![Page 27: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/27.jpg)
EORTC – Temozolomide + RT
27
![Page 28: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/28.jpg)
Temozolomide improved survival
28
![Page 29: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/29.jpg)
EORTC – Temozolomide + RT
The addition of temozolomide to standard radiation therapy improved survival:
• Median Overall Survival• 12 months to 16 months (4 month increase)
• 2 year Survival• 10 % to 25%
• 5 year Survival• 2% to 10%
As many patient were alive at 5 years with chemo/XRT, as were alive in 2 years with RT alone
29
![Page 30: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/30.jpg)
New Standard of Care in 2005
30
Surgery followed by:
6 weeks of XRT with concurrent TMZ(daily during XRT)
Then TMZ for 6 cycles(Taking TMX for the first 5 days of a 4 week cycle)
![Page 31: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/31.jpg)
Is that the best?
• From 2005 the standard of care was post operative radiation therapy with concurrent and adjuvant temozolomide
• 2 year overall survival increased from 10% to 27%
• 5 year overall survival improved from 1.9% to 9.8%• Same proportion of patients alive after 2 years
(10%) with surgery and RT• Now we see 10% living 5 years
31
![Page 32: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/32.jpg)
Is that the best?
• From 2005 the standard of care was post operative radiation therapy with concurrent and adjuvant temozolomide
• 2 year overall survival increased from 10% to 27%
• 5 year overall survival improved from 1.9% to 9.8%• Same proportion of patients alive after 2 years
(10%) with surgery and RT• Now we see 10% living 5 years
32
That means 75% will not live beyond 2 yearsAnd 90% will not live beyond 5 years
![Page 33: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/33.jpg)
Tumor Treating Fields (TTF)
•What are Tumor Treating Fields (TTF)• How does it work?• What does it look like?• Why do we use it?• How do patients use it?
Device using TTF tested and approved for GlioblastomaFirst new treatment approved in 10 years
33
![Page 34: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/34.jpg)
Tumor Treating Fields (TTF)
34
Alternating electrical fields designed to disrupt growing tumors
![Page 35: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/35.jpg)
What is TTF?
• TTF are low intensity, intermediate frequency alternating electric fields delivered in two directions
• Alternating electric fields cause interruption in cell growth, division, and can lead to cell death
35
![Page 36: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/36.jpg)
How does TTF work
36
![Page 37: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/37.jpg)
TTF affects both quiescent and dividing cells
37
![Page 38: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/38.jpg)
Cellular Effects of Electric Fields
38
![Page 39: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/39.jpg)
What does the device look like
39
Battery pack
Electrodes
![Page 40: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/40.jpg)
Tumor Treating Fields (TTF)
40
Approved for use in Glioblastoma in two situations
![Page 41: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/41.jpg)
Tumor Treating Fields (TTF)
41
Approved for use in Glioblastoma in two situations
More recent indication
![Page 42: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/42.jpg)
EF-14 Trial Design
42
![Page 43: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/43.jpg)
EF-14 Trial Design
43
Same as EORTC/Supp Trial
![Page 44: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/44.jpg)
EF-14 Trial Design
44
Same as EORTC/Supp Trial
Addition of TTF
![Page 45: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/45.jpg)
EF-14 Baseline Characteristics
45
Similar baseline characteristics
![Page 46: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/46.jpg)
EF-14 Progression Free Survival
46
![Page 47: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/47.jpg)
EF-14: Overall Survival
47
![Page 48: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/48.jpg)
EF-14: Overall Survival
48
4.5 month increase in media OS
![Page 49: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/49.jpg)
EF-14: Safety and Side Effects
49
The only significant difference in side effects were:Device site reactionsHeadaches
All other reactions were similar between two arms
![Page 50: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/50.jpg)
QOL Analysis from EF-14
50
QOL analysis showed patient had BETTER QOL with TTF in all marks (except itchy skin)
![Page 51: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/51.jpg)
Improvement in OS from 2005 to now
51
![Page 52: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/52.jpg)
Increases in survival
52
RT alone RT + TMZ RT + TMZ RT + TMZ + TTF
2 yr OS 10% 27% 31% 43%
5 yr OS 1.9% 9.8% 5% 13%
EORTC 26981-22981/NCIC CE3 EF-14 RT/TMZ +/- TTF
Up to 2005 2005 - 2016 2016 - ?
![Page 53: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/53.jpg)
Current Standard of Care
53
Both Category 1
![Page 54: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/54.jpg)
Current Standard of Care?
After 2005 when temozolomide was approved, it was noted that >75% of patients with glioblastoma were offered the drug
In 2018, 2 years after approval of Optune, approximately 30% of eligible patients are being actively prescribed
Despite same benefits to survival for Optune as we saw with TMZ
54
![Page 55: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/55.jpg)
Planning
55
Using Most Recent MRI to help design plan
![Page 56: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/56.jpg)
Planning
56
Using Most Recent MRI to help design plan
![Page 57: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/57.jpg)
Transduce Array Layout
57
![Page 58: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/58.jpg)
Preparing for placing the electrodes
•Prior to placement patients are instructed to•Wash his/her head. • Shave his/her entire scalp using an
electric shaver.•Wipe his/her scalp with 70% alcohol. •Use a high potency steroid cream if
scalp is red
58
![Page 59: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/59.jpg)
TTF Device Placed
59
Compliance can be hard,But it matters…
![Page 60: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/60.jpg)
Compliance of TTF
60
![Page 61: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/61.jpg)
Compliance of TTF
61
![Page 62: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/62.jpg)
Compliance of TTF
62
![Page 63: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/63.jpg)
Compliance of TTF
63
![Page 64: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/64.jpg)
Compliance of TTF
64
![Page 65: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/65.jpg)
Back to Case 1
• She underwent gross total resection.
• She received 60 Gy in 30 fractions with concurrent temozolomide
• She received adjuvant temozolomide (Stupp/EORTC)
• She initiated on OptuneTTF on 8/24/2017 (EF-14)
65
![Page 66: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/66.jpg)
Back to Case 1
• Her most recent scan continues to be without evidence of disease
• She is doing well
• She is wearing Optune98% of the time!
• Celebrating her 1 year anniversary of starting Optune with a party today
66
![Page 67: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/67.jpg)
Future Directions
67
![Page 68: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/68.jpg)
Future Directions
68
Using biomarkers to direct care
![Page 69: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/69.jpg)
Questions?
69
![Page 70: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/70.jpg)
Subgroups: Poor PS; Older
Not all patients are candidates for surgery, radiation and chemotherapy
Many patients are older and/or have poor performance status
Review of the use of radiation and/or chemotherapy in predominantly older patients (65-70 and older) with good or poor performance statuses
Is treatment one size fits all?
70
![Page 71: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/71.jpg)
Treatment in the Elderly
• Older patients were not equally represented in the clinical trials• EORTC had patients aged 18-70, with median age of 57
• Survival may be lower in patients over 65 years of age• Among elderly patients, median survival is markedly reduced at only 4–5
months, according to population-based studies (Iwamoto 2008; Barholtz-Sloan 2007)
• Older patients with more co-morbidities may not be able to tolerate standard treatment
• Should standard options be offered to all patients regardless of age?• Should performance status (KPS) affect treatment options?
71
![Page 72: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/72.jpg)
Treatment in the Elderly: KPS
72
Bedridden
Disabled/Needing Assistance
Normal Activity
![Page 73: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/73.jpg)
Case 2
• 71-year-old male history of heart disease, COPD who presented with foot pain, weakness and difficulty ambulating. KPS was approximately 60% at presentation
• He subsequently underwent imaging and MRI revealed bihemispheric supratentorial enhancing masses the largest being 5.5 cm
• Given the size of the lesions and bilateral tumors the patient was NOT a candidate for gross resection.
• The differential was lymphoma versus multifocal high-grade glioma or metastases
73
![Page 74: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/74.jpg)
Case 2
74
![Page 75: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/75.jpg)
Case 2
• He underwent open biopsy by neurosurgery
• The final pathology reported• Glioblastoma, WHO grade IV
• Molecular genetics:
• No MGMT methylation (poorer prognosis)
• No mutation in IDH1 or IDH2 (poorer prognosis)
75
![Page 76: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/76.jpg)
Treatment in the Elderly: Canadian Study
• Patients aged 60 and older with Glioblastoma• KPS was not part of stratification• All had KPS > 50 (ie, not Bedridden)
• Randomized to:• 60 Gy in 30 fractions (6 weeks)• Or 40 Gy in 15 fractions (3 weeks)
• No temozolomide• Study published in 2004, prior to TMZ as standard of care
• Outcomes• Overall survival similar in both arms• Can offer shorter course RT to older patients without compromising survival
76
![Page 77: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/77.jpg)
Treatment in the Elderly: Canadian Study
77
![Page 78: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/78.jpg)
Treatment in the Elderly: IAEA Trial
• Similar to prior study (Canadian Trial) authored by same group• Patients were one of two groups:
• 50 and older, with poor performance status (KPS 50-70)• Age 65 and older with good performance status (KPS > 70)
• Randomized to one of two radiation schedules• 40 Gy in 15 fractions (3 weeks)• 25 Gy in 5 fractions (1-2 weeks)
• No temozolomide
• Almost half (40%) of patients had poor PS (KPS 50-60)
78
![Page 79: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/79.jpg)
Treatment in the Elderly: IAEA Trial
79
Median survival:7.9 mo vs 6.4 mo(NS)
![Page 80: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/80.jpg)
Treatment in the Elderly: Nordic
• Nordic Trial
• Patients were > 60 years of age• Randomized to
• Conventional radiation, 60 Gy in 30 fractions (6 weeks)• Short course of radiation, 34 Gy in 10 fractions (2 weeks)• Temozolomide alone
• Longer course of XRT (6 weeks) did worse than short course RT or TMZ alone
• TMZ alone did better for patients with methylated MGMT
80
![Page 81: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/81.jpg)
Treatment in the Elderly: Nordic
81
![Page 82: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/82.jpg)
Treatment in the Elderly: NOA-08
• Age > 65, KPS > 60• RT or TMZ• Equal outcome for RT (60 Gy)
alone or TMZ alone• MGMT methylated did better
with TMZ alone (red)• MGMT unmethylated did better
with RT alone• Equal outcome with RT regardless of
MGMT status (blue and green)
82
![Page 83: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/83.jpg)
Treatment in the Elderly: Intergroup, 2017
CCTG/EORTC/TROG trial• Age greater than 65• Good performance status, ECOG PS 0-2 (~ KPS 70+)• Randomized to
• Radiation therapy alone (40 Gy in 15 fractions, 3 weeks)• XRT (40 Gy / 3 weeks) and Temozolomide
• Improved median surivial with 40 Gy/TMZ• 9.3 months vs 7.6 months
• Safe and effective to give TMZ with shorter course of XRT in good performance status patient over 65 yo
(Perry J, et al. NEJM 2017;376:1027)
83
![Page 84: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/84.jpg)
Treatment in the Elderly: Summary
• Elderly (65-70 and older), excellent KPS, surgery > 90%• Standard therapy, 60 Gy with TMZ, adjuvant TMZ (+ TTF)
• Elderly (65-70 and older), good KPS• Short course RT (40 Gy) with TMZ, and adjuvant TMZ
• Elderly (65-70 and older), lower KPS• Short course RT alone (40 Gy/3 weeks; 34 Gy/2 weeks)• TMZ alone in MGMT methylated
• Any age, and poor KPS• Short course RT alone (40 Gy/3 weeks; 34 Gy/2 weeks)• TMZ alone in MGMT methylated• Or Best supportive care
84
![Page 85: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/85.jpg)
Back to Case 2
• Given his age and his poor performance status at the time he was initially felt to be candidate for monotherapy.• He did not have MGMT methylation so short course radiation
therapy is contemplated
• After discharge his performance status improved (KPS 70-80%)
• He was then reconsidered for concurrent chemotherapy and radiation• He received 40 Gy in 15 fractions with temozolomide over 3 weeks
(EORTC)
• He had interval improvement for a month and was being considered for adjuvant chemotherapy and Optune
• Unfortunately, he had Progression,• He enrolled on hospice and died about 2-1/2 months after initiation
of treatment
85
![Page 86: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/86.jpg)
Recurrent Glioblastoma
86
Recurrent Disease
• How to define recurrence
• How to treat / Who to treat?
• Future directions
![Page 87: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/87.jpg)
Recurrent Glioblastoma
Recurrence in Glioblastoma is almost a certainty, as >99% recurrence or progression is seen in this disease
Treatment options for recurrence disease is just as important as primary treatment
Very few studies to generate a standard of care
PSEUDOPROGRESSION vs True Progression(next slide)
87
![Page 88: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/88.jpg)
Pseudoprogression
• Not all larger tumors are progressing• Pseudoprogression is defined as radiologic progression within first
three months that will stabilize or improve without additional treatment
• One month after chemo-radiotherapy• Half of tumors are bigger• 2/3 of those are Pseuoprogression• Patients with MGMT methylation are much more likely ot have
pseuoprogression
• Pseuoprogression has been associated with better survival in retrospective analysis (Brandes JCO 2008)
88
![Page 89: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/89.jpg)
RANO Criteria for Progression
89
Can only call PROGRESSIVE disease within 3 month if:Enhancement outside of RT fields, or biopsy proven
AFTER 3 MONTHS:
![Page 90: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/90.jpg)
Recurrent Glioblastoma
90
![Page 91: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/91.jpg)
Recurrent Glioblastoma
91
• Options for patients• Repeat Surgery
• Often limited by patient's performance status and/or size and location of recurrence precluding safe resection
• Anti-VEGF therapy, bevacizumab• Improved PFS, but not OS
• Chemotherapy• Repeat Temozolomide
• Lomustine, irinotecan
• Immune Therapy• Vaccine trials
• Peptide, virus, dendritic cells
• Anti PD/PDL1/CTLA drugs
![Page 92: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/92.jpg)
Recurrent Glioblastoma
92
• Options for patients (cont’d)• Repeat Radiation Therapy
• Re-irradiation
• Brachytherapy
• Stereotactic radiosurgery (SRS)
• Fractionated stereotactic radiation therapy (FSRT)
• Tumor Treating Fields (TTF)
• Clinical Trials
![Page 93: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/93.jpg)
Case 3
• 59-year-old female with history of glioblastoma diagnosed in 2009
• She underwent surgery and received adjuvant radiation therapy and temozolomide
• She did not tolerate temozolomide
• In 2011 she had recurrent disease and received chemotherapy with etoposide
• In 2014 she had another recurrence and received bevacizumab
93
![Page 94: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/94.jpg)
Back to Case 3
• She continued on bevacizumab until October 2017
• At that time she was diagnosed with recurrent glioblastoma• Her bevacizumab was then held
• Since this was a new location she was taken to the OR for repeat surgery
94
![Page 95: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/95.jpg)
Back to Case 3
95
![Page 96: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/96.jpg)
Recurrent Glioblastoma: Bevacizumab
• Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor
• A few initial studies demonstrated decreased use of glucocorticoids and increased PFS• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab
alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740
96
![Page 97: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/97.jpg)
Recurrent Glioblastoma: Bevacizumab
97
Selection of studies using antiVEGFtherapy.
Most without significant OS benefits, but promising PFS results
![Page 98: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/98.jpg)
Recurrent Glioblastoma: Bevacizumab
• Recently published phase III trial evaluated bevacizumab and lomustine vs lomustinemonotherapy.• Median overall survival: 9.1 months versus 8.6
month, NS
• Progression free survival 2.7 months longer in the combination group• Wick W, Gorlia T, Bendszus M, et al: Lomustine
and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954-1963, 2017.
98
![Page 99: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/99.jpg)
Recurrent Glioblastoma: Temozolomide
• Contradictory data exists regarding the use of temozolomide
• Initial study demonstrated benefit to temozolomide after relapse from standard chemotherapy• Trent S, Kong A, et al. J Neurooncol 2002
• Another study demonstrated benefit of temozolomidecompared to PCV chemotherapy and recurrent high-grade glioma• Brada, Stenning, et al. JCO 2010
• A meta-analysis of 33 phase 2 and retrospective study showed no significant overall survival benefit to dose dense temozolomide• Wei, Chen, Ma, et al. J Neurooncol 2015
99
![Page 100: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/100.jpg)
Recurrent Glioblastoma: PPV
100
Vaccine Trial
![Page 101: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/101.jpg)
Recurrent Glioblastoma: PPV
101
No improvement in OS
![Page 102: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/102.jpg)
Recurrent Glioblastoma: Immunotherapy
102
![Page 103: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/103.jpg)
Recurrent Glioblastoma: Radiation Therapy
• Re-irradiation of Glioblastoma has been reported in many institutional series
• Various dose and fraction schedules have been reported• Generally well tolerated• Uncertain benefit over other ‘salvage’ therapy
• RTOG has recently studied the use of 10 fraction radiation with Avastin for recurrent glioblastoma
• No reliable results yet
103
![Page 104: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/104.jpg)
Recurrent Glioblastoma: Radiation Therapy
104
![Page 105: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/105.jpg)
Recurrent Glioblastoma: TTF
105
![Page 106: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/106.jpg)
Recurrent Glioblastoma: TTF
106
![Page 107: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/107.jpg)
Recurrent Glioblastoma: TTF
107
![Page 108: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/108.jpg)
Recurrent Glioblastoma: TTF
108
![Page 109: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/109.jpg)
Recurrent Glioblastoma: TTF
109
![Page 110: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/110.jpg)
Recurrent Glioblastoma: TTF
110
EF-11: Summary
• The EF-11 phase 3 pivotal study was a large, randomized trial of patients with recurrent GBM
• TFFields as monotherapy demonstrated equivalent efficacy compared with chemotherapy (physician’s choice)
• The most common (>10%) adverse events seen with TTF monotherapy were device site reactions and headaches
![Page 111: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/111.jpg)
Back to Case 3
• After surgery she is felt to be a candidate for adjuvant radiation therapy.• She had prior poor tolerance to temozolomide therefore
this was not considered
• She received short course radiation therapy, 34 Gy in 10 fractions over 2 weeks (NORDIC trial)
• A cycle of lomustine was delivered• The patient tolerated this very poorly
• Based upon the EF 11 trial she initiated Optune in February of this year
111
![Page 112: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/112.jpg)
Back to Case 3
112
November 2017 February 2018 May 2018
![Page 113: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/113.jpg)
Back to Case 3
• She tolerated therapy with Optune very well for 5 months without any issues.
• Unfortunately she recently had progression of disease after 6 months on Optune TTF as salvage therapy
• She recently enrolled in hospice
113
![Page 114: Glioblastoma: Current Treatment Approach](https://reader033.fdocuments.us/reader033/viewer/2022061523/629f4850a9fede7c140d5536/html5/thumbnails/114.jpg)
Glioblastoma: Summary
• Challenging disease to treat• Standard of care is surgery, adjuvant chemo-radiation, TTF
• Advances in recent years• Improved understanding using newer molecular data• Advances in technology
• Need for further research studies
• Questions??
114